RESUMEN
Neuropeptides belonging to the adipokinetic hormone (AKH) family elicit metabolic effects as their main function in insects, by mobilizing trehalose, diacylgycerol, or proline, which are released from the fat body into the hemolymph as energy sources for muscle contraction required for energy-intensive processes, such as locomotion. One of the AKHs produced in locusts is a decapeptide, Locmi-AKH-I (pELNFTPNWGT-NH2). A head-to-tail cyclic, octapeptide analog of Locmi-AKH-I, cycloAKH (cyclo[LNFTPNWG]) was synthesized to severely restrict the conformational freedom of the AKH structure. In vitro, cycloAKH selectively retains full efficacy on a pest insect (desert locust) AKH receptor, while showing little or no activation of the AKH receptor of a beneficial insect (honeybee). Molecular dynamic analysis incorporating NMR data indicate that cycloAKH preferentially adopts a type II ß-turn under micelle conditions, whereas its linear counterpart and natural AKH adopts a type VI ß-turn under similar conditions. CycloAKH, linear LNFTPNWG-NH2, and Locmi-AKH-I feature the same binding site during docking simulations with the desert locust AKH receptor (Schgr-AKHR), but differ in the details of the ligand/receptor interactions. However, cycloAKH failed to enter the binding pocket of the honeybee receptor 3D model during docking simulations. Since the locust AKH receptor has a greater tolerance than the honeybee receptor for the cyclic conformational constraint in vitro receptor assays, it could suggest a greater tolerance for a shift in the direction of the type II ß turn exhibited by cycloAKH from the type VI ß turn of the linear octapeptide and the native locust decapeptide AKH. Selectivity in biostable mimetic analogs could potentially be enhanced by incorporating conformational constraints that emphasize this shift. Biostable mimetic analogs of AKH offer the potential of selectively disrupting AKH-regulated processes, leading to novel, environmentally benign control strategies for pest insect populations.
Asunto(s)
Abejas , Saltamontes , Hormonas de Insectos/agonistas , Oligopéptidos/agonistas , Ácido Pirrolidona Carboxílico/análogos & derivados , Receptores de Neuropéptido/química , Animales , Abejas/metabolismo , Sitios de Unión , Saltamontes/metabolismo , Control de Insectos , Hormonas de Insectos/síntesis química , Hormonas de Insectos/metabolismo , Proteínas de Insectos/química , Proteínas de Insectos/metabolismo , Imagen por Resonancia Magnética/métodos , Conformación Molecular , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Neuropéptidos/agonistas , Neuropéptidos/síntesis química , Neuropéptidos/metabolismo , Oligopéptidos/síntesis química , Oligopéptidos/metabolismo , Ácido Pirrolidona Carboxílico/agonistas , Ácido Pirrolidona Carboxílico/síntesis química , Ácido Pirrolidona Carboxílico/metabolismo , Receptores de Neuropéptido/metabolismoRESUMEN
Chronic opioids treatment is impeded by the development of analgesic tolerance and opioid-induced hyperalgesia. Recent studies have shown that multi-functional opioid compounds produce analgesic activities with limited side effects. We developed a novel multi-functional peptide targeting opioid and neuropeptide FF receptors named BN-9, which produced potent and non-tolerance forming antinociceptive effect after supraspinal and systemic administrations. In the present study, the analgesic properties and potential side effects of intrathecal BN-9 were investigated in a range of preclinical rodent models. In complete Freund's adjuvant-induced inflammatory pain model, intrathecal BN-9 dose-dependently produced analgesic effect via opioid receptors, and the spinal antinociceptive effect was augmented by the neuropeptide FF receptor antagonist RF9. In contrast, in plantar incision-induced postoperative pain model, BN-9 exhibited potent anti-allodynic effect via opioid receptors and, at least partially, neuropeptide FF receptors. In mouse models of acetic acid-induced visceral pain and formalin pain, BN-9-induced spinal antinociception was mainly mediated by opioid receptors, independent of neuropeptide FF receptors. Furthermore, at the spinal level, chronic treatments with BN-9 did not lead to analgesic tolerance and cross-tolerance to morphine. Moreover, opioid-induced hyperalgesia was observed after repeated administration of morphine, but not BN-9. Taken together, our present study suggests that intrathecal BN-9 produces potent and non-tolerance forming antinociception, and does not cause opioid-induced hyperalgesia. Thus, BN-9 might serve as a promising lead compound in the development of multi-functional opioid analgesics with minimized side effects.
Asunto(s)
Analgésicos Opioides/uso terapéutico , Oligopéptidos/agonistas , Oligopéptidos/uso terapéutico , Dolor/tratamiento farmacológico , Ácido Acético , Analgésicos Opioides/efectos adversos , Animales , Tolerancia a Medicamentos , Fascia/lesiones , Formaldehído , Calor/efectos adversos , Hiperalgesia/inducido químicamente , Inyecciones Espinales , Masculino , Ratones , Morfina/efectos adversos , Morfina/uso terapéutico , Dolor/etiología , Ratas WistarRESUMEN
The effect of Habrobracon hebetor venom and the role of the adipokinetic hormone (AKH) in poisoned adult females of the firebug Pyrrhocoris apterus were studied 24 and 48h after treatments. Venom application elicited total neuromuscular paralysis in firebugs, but the co-application of venom and Pyrap-AKH significantly reduced paralysis (up to 3.2 times) compared to the application of venom only. Although the mechanisms of their action are unknown, both agents might affect neuromuscular junctions. Venom application significantly increased the expression of both P. apterus Akh genes (Pyrap-Akh 5.4 times and Peram-Cah-II 3.6 times), as well as the level of AKHs in the central nervous system (2.5 times) and haemolymph (3.0 times). In the haemolymph, increased AKH levels might have led to the mobilization of stored lipids, which increased 1.9 times, while the level of free carbohydrates remained unchanged. Total metabolism, monitored by carbon dioxide production, significantly declined in paralysed P. apterus individuals (1.4 times and 1.9 times, 24 and 48h after the treatment, respectively), probably because of a malfunction of the muscular system. The results suggest an active role of AKH in the defence mechanism against the stress elicited by neuromuscular paralysis, and the possible involvement of this hormone in neuronal/neuromuscular signalling.
Asunto(s)
Sistema Nervioso Central/efectos de los fármacos , Heterópteros/efectos de los fármacos , Hormonas de Insectos/agonistas , Neuropéptidos/fisiología , Oligopéptidos/agonistas , Parálisis/veterinaria , Ácido Pirrolidona Carboxílico/análogos & derivados , Regulación hacia Arriba/efectos de los fármacos , Venenos de Avispas/toxicidad , Alostasis , Animales , Biomarcadores/metabolismo , Sistema Nervioso Central/metabolismo , República Checa , Relación Dosis-Respuesta a Droga , Metabolismo Energético/efectos de los fármacos , Femenino , Hemolinfa/efectos de los fármacos , Hemolinfa/metabolismo , Heterópteros/fisiología , Inyecciones , Hormonas de Insectos/genética , Hormonas de Insectos/metabolismo , Hormonas de Insectos/fisiología , Cinética , Unión Neuromuscular/efectos de los fármacos , Unión Neuromuscular/fisiología , Neuropéptidos/agonistas , Neuropéptidos/análisis , Neuropéptidos/genética , Neuropéptidos/metabolismo , Oligopéptidos/genética , Oligopéptidos/metabolismo , Oligopéptidos/fisiología , Parálisis/inducido químicamente , Ácido Pirrolidona Carboxílico/agonistas , Tórax , Venenos de Avispas/antagonistas & inhibidores , Venenos de Avispas/aislamiento & purificaciónRESUMEN
Neuropeptide FF (NPFF) has been implicated in many physiological processes. Previously, we have reported that NPFF modulates the viability and nitric oxide (NO) production of RAW264.7 macrophages. In this study, we investigated the influence of NPFF on lipopolysaccharide (LPS)-mediated osteoclast formation of RAW264.7 cells. Our results suggest that, NPFF dose-dependently (1 nM, 10 nM and 100 nM) inhibited osteoclast formation, TRAP enzyme activity and bone resorption in osteoclasts induced by LPS respectively. Moreover, LPS-provoked NO release was also inhibited by NPFF treatment, indicating a NO-dependent pathway is mainly involved. Furthermore, the alterations of osteoclast marker genes were also assessed including TRAP, Cathepsin K, MMP-9, NFATc1 and Runx2. NPFF downregulated LPS-caused gene augmentations of TRAP, Cathepsin K and MMP-9, whereas showed no influences on NFATc1 and Runx2. In addition, NPFF receptor 2 (NPFFR2) mRNA expression was also augmented in response to NPFF treatment, hinting the involvement of NPFFR2 pathway. It should be mentioned that RF9 (1 µ M), a reported pharmacological inhibitor for NPFF receptors, exerted NPFF-like agonist properties as to attenuate osteoclastogenesis. Collectively, our findings provide new evidence for the in vitro activity of NPFF on osteoclasts, which may be helpful to extend the scope of NPFF functions.
Asunto(s)
Lipopolisacáridos/farmacología , Macrófagos/efectos de los fármacos , Oligopéptidos/farmacología , Osteoclastos/efectos de los fármacos , Receptores de Neuropéptido/genética , Fosfatasa Ácida/metabolismo , Adamantano/análogos & derivados , Adamantano/farmacología , Animales , Diferenciación Celular/efectos de los fármacos , Línea Celular , Dipéptidos/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Técnicas In Vitro , Isoenzimas/metabolismo , Macrófagos/citología , Ratones , Oligopéptidos/agonistas , Osteoclastos/metabolismo , Fosfatasa Ácida Tartratorresistente , Regulación hacia ArribaRESUMEN
There is a compelling need for the development of small molecule agonists acting at family B G protein-coupled receptors. A possible lead for the development of such drugs was reported when it was recognized that sequences endogenous to the amino terminus of the secretin receptor and certain other receptors in this family possess weak full agonist activity (Dong et al. Mol Pharmacol 2006;70:206-213). In the current report, we extended those observations by building the active dipeptide motif found in the secretin receptor (WD) into each position around a conformationally constrained d-amino acid-containing cyclic hexapeptide, and determining the biological activity of each peptide at the secretin receptor. Indeed, only two positions for WD around this constrained ring resulted in biological activity at the receptor, providing further insights into the structural specificity of this phenomenon. Molecular modeling supported the presence of a unique WD backbone conformation shared only by these active peptides, and provided a more constrained template for future receptor-active agonist drug development.
Asunto(s)
Oligopéptidos , Péptidos Cíclicos/química , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/química , Receptores de la Hormona Gastrointestinal/agonistas , Receptores de la Hormona Gastrointestinal/química , Animales , Células CHO , Cricetinae , Cricetulus , AMP Cíclico/metabolismo , Ligandos , Modelos Moleculares , Oligopéptidos/agonistas , Conformación Proteica , Relación Estructura-ActividadRESUMEN
The kisspeptins are neuropeptides that stimulate the hypothalamo-pituitary-gonadal (HPG) axis. The smallest endogenous kisspeptin, kisspeptin-10 (KP-10), binds to the receptor KISS1R with a similar affinity to the full-length peptide, kisspeptin-54 (KP-54), but is less effective in vivo, possibly because of increased enzymatic breakdown or clearance. The kisspeptin system may have therapeutic potential in the treatment of reproductive disorders and endocrine cancers. We have rationally modified the structure of KP-10 and tested the binding affinity of these analogs for the KISS1R. Those analogs that bound with relatively high affinity to KISS1R were tested for ability to stimulate ERK1/2 phosphorylation in vitro and for their ability to stimulate the HPG axis in vivo. One analog, [dY](1)KP-10, bound to KISS1R with lower affinity to KP-10 and exhibited similar bioactivity in vitro. However, in vivo peripheral administration of [dY](1)KP-10 increased plasma LH and testosterone more potently than KP-10 itself at 20 min postinjection in mice. In addition, 60 min postinjection, 0.15 nmol [dY](1)KP-10 significantly increased total testosterone levels in mice whereas the same dose of KP-10 had no significant effect. Should manipulation of the kisspeptin/KISS1R signaling system prove therapeutically useful, long-lasting analogs such as [dY](1)KP-10 may have greater therapeutic potential than endogenous forms of kisspeptin.
Asunto(s)
Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Neuropéptidos/agonistas , Oligopéptidos/agonistas , Receptores Acoplados a Proteínas G/efectos de los fármacos , Secuencia de Aminoácidos , Animales , Bioensayo , Humanos , Kisspeptinas , Masculino , Ratones , Ratones Endogámicos C57BL , Neuropéptidos/farmacología , Sistemas Neurosecretores/efectos de los fármacos , Oligopéptidos/farmacología , Testículo/efectos de los fármacosRESUMEN
We determined the expression of the formyl peptide receptor (FPR) family and the functional roles of the FPR family in NK cells. All tested human NK cells express two members of the FPR family (FPR1 and FPR2). The expression of FPR3 was noted to occur in a donor-specific manner. The stimulation of NK cells with FPR family-selective agonists (fMLF (N-formyl-Met-Leu-Phe), MMK-1, F2L, and WKYMVm (Trp-Lys-Tyr-Met-Val-d-Met)) elicited cytolytic activity in resting NK cells, but not in IL-2-activated NK cells; the cytolytic activity was not inhibited by pertussis toxin. The FPR family agonists also stimulated chemotactic migration of IL-2-activated NK cells, but not resting NK cells; the chemotactic migration was completely inhibited by pertussis toxin. WKYMVm stimulates ERK, p38 MAPK, and JNK activities in both resting and IL-2-activated NK cells. WKYMVm-induced chemotactic migration was partially inhibited by PD98059 (2'-amino-3'-methoxyflavone); however, the inhibition of JNK by its selective inhibitor (SP600125, anthra[1,9-cd]pyrazol-6(2H)-one) dramatically inhibited the WKYMVm-induced cytolytic activity. Furthermore, WKYMVm-induced chemotactic migration and cytolytic activity were partly inhibited by FPR family-selective antagonists (cyclosporin H and WRWWWW). Taken together, our findings indicate that human NK cells express functional members of the FPR family, and in turn the activation of the three members of the FPR receptor family elicit cytolytic activity in NK cells, thus suggesting that the receptors are potentially important therapeutic targets for the modulation of NK cell-mediated immune responses.
Asunto(s)
Células Asesinas Naturales/inmunología , Células Asesinas Naturales/metabolismo , Familia de Multigenes/inmunología , Receptores de Formil Péptido/biosíntesis , Quimiotaxis de Leucocito/inmunología , Citotoxicidad Inmunológica , Humanos , Activación de Linfocitos/inmunología , Oligopéptidos/agonistas , Oligopéptidos/biosíntesis , Oligopéptidos/fisiología , Receptores de Formil Péptido/agonistas , Receptores de Formil Péptido/fisiología , Receptores de Lipoxina/agonistas , Receptores de Lipoxina/biosíntesis , Receptores de Lipoxina/fisiología , Transducción de Señal/inmunologíaRESUMEN
BACKGROUND: Isolated limb infusion with melphalan is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximately 30% complete response (CR) rate. ADH-1 is a cyclic pentapeptide that disrupts N-cadherin adhesion complexes and when given systemically in a preclinical model of regional melphalan therapy demonstrated synergistic antitumor activity. A phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with in-transit extremity melanoma was performed. METHODS: Dose escalation cohorts of 3 patients each received 1000, 2000, and 4000 mg (10 patients) of ADH-1 administered intravenously on Days 1 and 8 with standard dose melphalan via isolated limb infusion on Day 1. N-cadherin immunohistochemistry staining and quantitative polymerase chain reaction analysis were performed on pretreatment tumor. Response was defined at 3 months using modified Response Evaluation Criteria in Solid Tumors. RESULTS: Sixteen patients have been treated with no observed dose-limiting toxicities. Common treatment-related grade 1 or 2 toxicities included skin/dermatologic (n=14) and pain (n=12). Grade 3 toxicities included shortness of breath (n=1), hypertension (n=1), serologic toxicities (n=4), and 1 grade 4 creatine phosphokinase elevation. In-field responses included 8 CRs, 2 partial responses, 1 stable disease, and 5 progressive diseases. Pharmacokinetic analysis demonstrated increasing ADH-1 concentrations at each dose and minimal variability in melphalan drug levels. CONCLUSIONS: Systemic ADH-1 at a dose of 4000 mg on Days 1 and 8 in combination with melphalan via isolated limb infusion is a well-tolerated, novel targeted therapy approach to regionally advanced melanoma. The number of CRs exceeded expectations, suggesting that targeting N-cadherin may be a new strategy for overcoming melanoma chemoresistance.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Melanoma/tratamiento farmacológico , Melfalán/administración & dosificación , Oligopéptidos/administración & dosificación , Péptidos Cíclicos/administración & dosificación , Neoplasias Cutáneas/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Quimioterapia del Cáncer por Perfusión Regional , Esquema de Medicación , Extremidades , Femenino , Humanos , Masculino , Melanoma/patología , Oligopéptidos/efectos adversos , Oligopéptidos/agonistas , Péptidos Cíclicos/efectos adversos , Péptidos Cíclicos/agonistas , Neoplasias Cutáneas/patología , Análisis de SupervivenciaRESUMEN
Glycine-proline-glutamate (GPE) is an N-terminal tripeptide endogenously cleaved from insulin-like growth factor-1 in the brain and is neuroprotective against hypoxic-ischemic brain injury and neurodegeneration. NNZ-2566 is an analog of GPE designed to have improved bioavailability. In this study, we tested NNZ-2566 in a rat model of penetrating ballistic-type brain injury (PBBI) and assessed its effects on injury-induced histopathology, behavioral deficits, and molecular and cellular events associated with inflammation and apoptosis. In the initial dose-response experiments, NNZ-2566 (0.01-3 mg/kg/h x 12 h intravenous infusion) was given at 30 min post-injury and the therapeutic time window was established by delaying treatments 2-4 h post-injury, but with the addition of a 10- or 30-mg/kg bolus dose. All animals survived 72 h. Neuroprotection was evaluated by balance beam testing and histopathology. The effects of NNZ-2566 on injury-induced changes in Bax and Bcl-2 proteins, activated microgliosis, neutrophil infiltration, and astrocyte reactivity were also examined. Behavioral results demonstrated that NNZ-2566 dose-dependently reduced foot faults by 19-66% after acute treatments, and 35-55% after delayed treatments. Although gross lesion volume was not affected, NNZ-2566 treatment significantly attenuated neutrophil infiltration and reduced the number of activated microglial cells in the peri-lesion regions of the PBBI. PBBI induced a significant upregulation in Bax expression (36%) and a concomitant downregulation in Bcl-2 expression (33%), both of which were significantly reversed by NNZ-2566. Collectively, these results demonstrated that NNZ-2566 treatment promoted functional recovery following PBBI, an effect related to the modulation of injury-induced neural inflammatory and apoptotic mechanisms.
Asunto(s)
Apoptosis/efectos de los fármacos , Lesiones Encefálicas/tratamiento farmacológico , Encefalitis/tratamiento farmacológico , Fármacos Neuroprotectores/farmacología , Oligopéptidos/farmacología , Recuperación de la Función/efectos de los fármacos , Animales , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Apoptosis/fisiología , Proteínas Reguladoras de la Apoptosis/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/metabolismo , Astrocitos/efectos de los fármacos , Astrocitos/patología , Encéfalo/efectos de los fármacos , Encéfalo/patología , Encéfalo/fisiopatología , Lesiones Encefálicas/metabolismo , Lesiones Encefálicas/fisiopatología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Encefalitis/metabolismo , Encefalitis/fisiopatología , Gliosis/tratamiento farmacológico , Gliosis/fisiopatología , Gliosis/prevención & control , Inyecciones Intravenosas , Microglía/efectos de los fármacos , Microglía/patología , Trastornos del Movimiento/tratamiento farmacológico , Trastornos del Movimiento/etiología , Trastornos del Movimiento/fisiopatología , Degeneración Nerviosa/tratamiento farmacológico , Degeneración Nerviosa/fisiopatología , Degeneración Nerviosa/prevención & control , Fármacos Neuroprotectores/uso terapéutico , Oligopéptidos/agonistas , Oligopéptidos/química , Oligopéptidos/uso terapéutico , Ratas , Ratas Sprague-Dawley , Recuperación de la Función/fisiología , Resultado del TratamientoRESUMEN
Human platelets express protease-activated receptor 1 (PAR1) and PAR4 but limited data indicate for differences in signal transduction. We studied the involvement of PAR1 and PAR4 in the cross-talk between thrombin and epinephrine. The results show that epinephrine acted via alpha(2A)-adrenergic receptors to provoke aggregation, secretion, and Ca(2+) mobilization in aspirin-treated platelets pre-stimulated with subthreshold concentrations of thrombin. Incubating platelets with antibodies against PAR4 or the PAR4-specific inhibitor pepducin P4pal-i1 abolished the aggregation. Furthermore, platelets pre-exposed to the PAR4-activating peptide AYPGKF, but not to the PAR1-activating peptide SFLLRN, were aggregated by epinephrine, whereas both AYPGKF and SFLLRN synergized with epinephrine in the absence of aspirin. The roles of released ATP and ADP were elucidated by using antagonists of the purinergic receptors P2X(1), P2Y(1), and P2Y(12) (i.e. NF449, MRS2159, MRS2179, and cangrelor). Intriguingly, ATP, but not ADP, was required for the epinephrine/thrombin-induced aggregation. In Western blot analysis, a low concentration of AYPGKF, but not SFLLRN, stimulated phosphorylation of Akt on serine 473. Moreover, the phosphatidyl inositide 3-kinase inhibitor LY294002 antagonized the effect of epinephrine combined with thrombin or AYPGKF. Thus, in aspirin-treated platelets, PAR4, but not PAR1, interacts synergistically with alpha(2A)-adrenergic receptors, and the PI3-kinase/Akt pathway is involved in this cross-talk. Furthermore, in PAR4-pretreated platelets, epinephrine caused dense granule secretion, and subsequent signaling from the ATP-gated P2X(1)-receptor and the alpha(2A)-adrenergic receptor induced aggregation. These results suggest a new mechanism that has ATP as a key element and circumvents the action of aspirin on epinephrine-facilitated PAR4-mediated platelet activation.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacología , Aspirina/farmacología , Plaquetas/metabolismo , Epinefrina/farmacología , Hemostáticos/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Receptores Adrenérgicos alfa 2/metabolismo , Receptores Purinérgicos P2/metabolismo , Receptores de Trombina/metabolismo , Trombina/farmacología , Adenosina Difosfato/metabolismo , Adenosina Trifosfato/metabolismo , Agonistas de Receptores Adrenérgicos alfa 2 , Antagonistas de Receptores Adrenérgicos alfa 2 , Aspirina/agonistas , Aspirina/antagonistas & inhibidores , Plaquetas/citología , Calcio/farmacología , Cromonas/farmacología , Relación Dosis-Respuesta a Droga , Antagonismo de Drogas , Sinergismo Farmacológico , Inhibidores Enzimáticos/farmacología , Epinefrina/agonistas , Epinefrina/antagonistas & inhibidores , Humanos , Morfolinas/farmacología , Oligopéptidos/agonistas , Oligopéptidos/antagonistas & inhibidores , Oligopéptidos/farmacología , Fragmentos de Péptidos/agonistas , Fragmentos de Péptidos/antagonistas & inhibidores , Fragmentos de Péptidos/farmacología , Fosfatidilinositol 3-Quinasas/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3 , Agregación Plaquetaria/fisiología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Agonistas Purinérgicos , Agonistas del Receptor Purinérgico P2 , Receptor PAR-1/agonistas , Receptor PAR-1/metabolismo , Receptores Purinérgicos/metabolismo , Receptores Purinérgicos P2X , Receptores de Trombina/agonistas , Vesículas Secretoras/metabolismo , Trombina/agonistas , Trombina/antagonistas & inhibidoresRESUMEN
BACKGROUND: High tidal volume ventilation can cause inflammatory reaction in lungs. Integrins are associated with regulating lung inflammation and edema following acute lung injury. Integrin alpha v beta 6 expression in ventilator-induced lung injury (VILI) and the ability of the RGD-peptidomimetic agent S247 to attenuate VILI in rats were investigated. MATERIAL/METHODS: Eighteen adult male rats were assigned to three groups: controls (C: n=6) with no ventilation; high tidal volume lung ventilation (H: n=6); and such ventilation after treatment with S247 (HS: n=6). HS was injected with 50 mg/kg S247 18 h before and then i.p injection every 3 h until the start of ventilation. The others received saline. Assessed were lung histopathology, wet-to-dry weight ratios, total protein content, white blood cell (WBC) counts, macrophage inflammatory protein-2 (MIP-2), and tumor necrosis factor-alpha (TNF-alpha) concentrations in the bronchoalveolar lavage fluid (BALF) and integrin alpha v beta 6 mRNA and protein expression. RESULTS: Wet-to-dry weight ratios and BALF WBCs and total protein content were different among the groups (p<0.01). Lung injury score and integrin alpha v beta 6 mRNA level were lower in HS than in H (p<0.01). Integrin alpha v beta 6-positive staining was mainly on alveolar walls and the immunoreactivity of HS was clearly less than in H. TNF-alpha was not detected in C and was significantly lower in HS than in H (p<0.05). MIP-2 concentration in H was higher than in C and HS (p<0.01). CONCLUSIONS: Pretreatment with S247 attenuated VILI, suggesting pulmonary epithelial integrins are involved in its pathogenesis and agents such as S247 may be useful in treating it.
Asunto(s)
Antígenos de Neoplasias/metabolismo , Integrinas/antagonistas & inhibidores , Integrinas/metabolismo , Lesión Pulmonar , Pulmón/efectos de los fármacos , Compuestos Orgánicos/farmacología , Animales , Antígenos de Neoplasias/genética , Secuencia de Bases , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Citocinas/metabolismo , Cartilla de ADN/genética , Expresión Génica/efectos de los fármacos , Integrinas/genética , Recuento de Leucocitos , Pulmón/metabolismo , Masculino , Oligopéptidos/agonistas , Compuestos Orgánicos/síntesis química , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Respiración Artificial/efectos adversosRESUMEN
Little is known about the interplay between pathophysiological processes of allergy and infection, particularly with respect to mast cell (MC)-mediated responses. The presence and recognition of pathogen-associated molecular patterns (PAMPs) might have broad impact on the development and severity of diseases. In this study, we assessed the influence of toll-like receptor 2 (TLR 2)-dependent synthetic analogs of bacterial lipopeptides (LPs), Pam(3)CSK(4) and MALP-2, on Ag (DNP-HSA)-triggered responses in bone marrow-derived MCs (BMMCs). Both LPs strongly synergized with sub-optimal amounts of Ag in the stimulation of cytokine release. Intriguingly, Pam(3)CSK(4), but not MALP-2 suppressed Ag-induced degranulation of BMMCs (together with early tyrosine phosphorylation and calcium mobilization) in a TLR2-independent manner. Further analysis revealed that Pam(3)CSK(4), most probably by electrostatic forces, reduced the level of active DNP-HSA and that this, in turn, was responsible for the suppression of Ag-induced degranulation. Thus, our work demonstrates that LPs can synergize with IgE+Ag in stimulating the production of IL-6 by BMMCs. As well, our findings with Pam(3)CSK(4) indicate that one must be cautious when interpretating results obtained with "model" substances and the combination of ligands must be carefully chosen when functional interactions between the high-affinity receptor for IgE (FcepsilonR1) and TLR2 are examined.
Asunto(s)
Antígenos Bacterianos/farmacología , Proteínas Bacterianas/farmacología , Inmunoglobulina E/farmacología , Mastocitos/inmunología , Oligopéptidos/farmacología , Receptores de IgE/agonistas , Receptor Toll-Like 2/agonistas , Animales , Antígenos Bacterianos/inmunología , Proteínas Bacterianas/agonistas , Proteínas Bacterianas/inmunología , Células de la Médula Ósea/citología , Células de la Médula Ósea/inmunología , Señalización del Calcio/efectos de los fármacos , Señalización del Calcio/inmunología , Células Cultivadas , Citocinas/inmunología , Sinergismo Farmacológico , Hipersensibilidad/inmunología , Inmunoglobulina E/inmunología , Infecciones/inmunología , Ligandos , Masculino , Mastocitos/citología , Ratones , Modelos Inmunológicos , Oligopéptidos/agonistas , Oligopéptidos/inmunología , Fosforilación/efectos de los fármacos , Receptores de IgE/inmunología , Receptor Toll-Like 2/inmunologíaRESUMEN
ShcA proteins mediate Erk1/Erk2 activation by integrins and epidermal growth factor (EGF), and are expressed as p46ShcA, p52ShcA, and p66ShcA. Although p52ShcA and p46ShcA mediate Erk1/Erk2 activation, p66ShcA antagonizes Erk activation. p66ShcA is spatially regulated during lung development, leading us to hypothesize that integrin signaling regulates p66ShcA expression and, consequently, EGF signaling. Fetal lung mesenchymal cells were isolated from E16 Swiss-Webster mice, stimulated with oligopeptide extracellular matrix analogs or anti-integrin antibodies, and subjected to ShcA Western analyses and EGF-stimulated Erk1/Erk2 kinase assays. p66ShcA expression was decreased by anti-alpha1 integrin antibody and DGEA collagen analog, and increased by anti-beta1, anti-alpha4, and anti-alpha5 integrin antibodies and RGDS fibronectin analog. Paradoxically, beta1 integrin stimulation increased EGF-induced Erk activation while increasing expression of the inhibitory p66ShcA isoform. This paradox was resolved by demonstrating that Erk inhibition attenuates integrin-mediated p66ShcA induction. These results suggest that p66ShcA is up-regulated as inhibitory feedback on integrin-mediated Erk activation.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Factor de Crecimiento Epidérmico/farmacología , Feto/citología , Regulación de la Expresión Génica/efectos de los fármacos , Integrina beta1/metabolismo , Pulmón/citología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Animales , Anticuerpos/inmunología , Anticuerpos/farmacología , Técnicas de Cultivo de Célula , Separación Celular , Activación Enzimática/efectos de los fármacos , Matriz Extracelular/metabolismo , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Integrina beta1/inmunología , MAP Quinasa Quinasa 1/antagonistas & inhibidores , Mesodermo/citología , Ratones , Oligopéptidos/agonistas , Isoformas de Proteínas/metabolismo , Proteínas Adaptadoras de la Señalización Shc , Proteína Transformadora 1 que Contiene Dominios de Homología 2 de Src , Regulación hacia Arriba/genéticaRESUMEN
Neuropeptide FF behaves as an opioid-modulating peptide that seems to be involved in morphine tolerance and physical dependence. Nevertheless, the effects of neuropeptide FF agonists on the rewarding properties of morphine remain unknown. C57BL6 mice were conditioned in an unbiased balanced paradigm of conditioned place preference to study the effect of i.c.v. injections of 1DMe (D-Tyr1(NMe)Phe3]NPFF), a stable agonist of the neuropeptide FF system, on the acquisition of place conditioning by morphine or alcohol (ethanol). Morphine (10 mg/kg, i.p.) or ethanol (2 g/kg, i.p.) induced a significant place preference. Injection of 1DMe (1-20 nmol), given 10 min before the i.p. injection of the reinforcing drug during conditioning, inhibited the rewarding effect of morphine but had no effect on the rewarding effect of ethanol. However, a single injection of 1DMe given just before place preference testing was unable to inhibit the rewarding effects of morphine. By itself, 1DMe was inactive but an aversive effect of this agonist could be evidenced if the experimental procedure was biased. These results suggest that neuropeptide FF, injected during conditioning, should influence the development of rewarding effects of morphine and reinforce the hypothesis of strong inhibitory interactions between neuropeptide FF and opioids.
Asunto(s)
Condicionamiento Psicológico/efectos de los fármacos , Morfina/farmacología , Oligopéptidos/agonistas , Oligopéptidos/farmacología , Animales , Reacción de Prevención/efectos de los fármacos , Etanol/farmacología , Femenino , Inyecciones Intraventriculares , Ratones , Ratones Endogámicos C57BL , Receptores de Neuropéptido/agonistas , RecompensaRESUMEN
The partial mu-opioid receptor pool inactivation strategy in isolated mouse vas deferens was used to determine partial agonism of endomorphins and their analogs (endomorphin-1-ol, 2',6'-dimethyltyrosine (Dmt)-endomorphin-1, endomorphin-2-ol and (D-Met2)-endomorphin-2) using morphine, normorphine, morphiceptin, (D-Ala2,MePhe4,Gly5-ol)-enkephalin (DAMGO) and its amide (DAMGA) as reference opioid agonists. Agonist affinities (KA) and efficacies were assessed both by the "null" and the "operational" method. The KA values determined by the two methods correlated significantly with each other and also with the displacing potencies against 3H-naloxone in the receptor binding assay in the presence of Na+. DAMGO and DAMGA were full agonist prototypes, morphine, endomorphin-1, endomorphin-1-ol, Dmt-endomorphin-1, endomorphin-2-ol and (D-Met2)-endomorphin-2 were found by both methods to be partial agonists whereas the parameters for normorphine, morphiceptin and endomorphin-2 were intermediate.
Asunto(s)
Oligopéptidos/agonistas , Oligopéptidos/química , Animales , Encéfalo/metabolismo , Relación Dosis-Respuesta a Droga , Endorfinas/química , Encefalina Ala(2)-MeFe(4)-Gli(5)/análogos & derivados , Encefalina Ala(2)-MeFe(4)-Gli(5)/farmacología , Masculino , Ratones , Derivados de la Morfina/química , Naloxona/química , Oligopéptidos/metabolismo , Ratas , Receptores Opioides mu/metabolismo , Conducto Deferente/metabolismoRESUMEN
The paraventricular nucleus of the hypothalamus contains the cell bodies of a group of oxytocinergic neurons projecting to extrahypothalamic brain areas and to the spinal cord, which are involved in the control of erectile function and copulation. In male rats, these neurons can be activated by dopamine, excitatory amino acids, nitric oxide (NO), hexarelin analogue peptides and oxytocin itself to induce penile erection and facilitate copulation, while their inhibition by gamma-aminobutyric acid (GABA) and GABA agonists and by opioid peptides and opiate-like drugs inhibits sexual responses. The activation of paraventricular oxytocinergic neurons by dopamine, oxytocin, excitatory amino acids and hexarelin analogue peptides is apparently mediated by the activation of nitric oxide (NO) synthase. NO in turn activates, by a mechanism that is as yet unidentified, the release of oxytocin from oxytocinergic neurons in extrahypothalamic brain areas. Paraventricular oxytocinergic neurons and mechanisms similar to those reported above are also involved in the expression of penile erection in physiological contexts, namely, when penile erection is induced in the male by the presence of an inaccessible receptive female, which is considered a model for psychogenic impotence in man, as well as during copulation. These findings show that paraventricular oxytocinergic neurons projecting to extrahypothalamic brain areas and to the spinal cord and the paraventricular nucleus play an important role in the control of erectile function and male sexual behaviour in mammals.
Asunto(s)
Mamíferos/fisiología , Neuronas/fisiología , Oxitocina/fisiología , Núcleo Hipotalámico Paraventricular/fisiología , Conducta Sexual Animal/fisiología , Animales , Aminoácidos Excitadores/fisiología , Masculino , Vías Nerviosas/citología , Vías Nerviosas/fisiología , Neuropéptidos/fisiología , Óxido Nítrico/fisiología , Oligopéptidos/agonistas , Oligopéptidos/fisiología , Núcleo Hipotalámico Paraventricular/citología , Erección Peniana/fisiología , Ratas , Caracteres Sexuales , Factores Sexuales , Ácido gamma-Aminobutírico/fisiologíaRESUMEN
Active thrombin is found in the airways of patients with a variety of inflammatory lung diseases. However, whether thrombin contributes to the pathologies of these diseases is unknown, although thrombin is a potent inflammatory mediator in other organ systems. In the present study we have assessed the acute inflammatory effect of inhaled thrombin and investigated the possible receptors mediating any effects in mice. Thrombin (200-2000 U kg(-1) intranasally), induced the recruitment of a small, but significant, number of neutrophils into the airways as assessed by differential counts of cells retrieved by bronchoalveolar lavage (BAL). This small response was mimicked by peptide agonists of proteinase-activated receptor-4 (PAR(4); GYPGKF, AYPGKF; 2-20 mg kg(-1)), but not PAR(1) (SFLLRN; 2-20 mg kg(-1)). By contrast, trypsin (200-2000 U kg(-1)) caused profound inflammation and lung damage. Concentrations of tumour necrosis factor-alpha (TNF-alpha) were elevated in BAL fluid from thrombin-treated mice, and a TNF-alpha-neutralising antibody inhibited the influx of neutrophils in response to thrombin. Although isolated alveolar macrophages appeared to express PAR(1)- and PAR(4)-immunoreactivity, these cells failed to release TNF-alpha above baseline levels in response to thrombin, trypsin or any of the peptide PAR agonists. Neither thrombin (2000 U kg(-1)) nor trypsin (200 U kg(-1)) modified the airway neutrophilia in response to intranasal bacterial lipopolysaccharide (LPS; 100 micrograms kg(-1)). In conclusion, exogenous thrombin has only a modest acute inflammatory action in the lung that appears to be mediated by PAR(4) and involve release of TNF-alpha from an unknown source.
Asunto(s)
Receptores de Trombina/administración & dosificación , Receptores de Trombina/agonistas , Administración por Inhalación , Administración Intranasal , Animales , Líquido del Lavado Bronquioalveolar/citología , Células Epiteliales/citología , Células Epiteliales/efectos de los fármacos , Femenino , Inflamación/inducido químicamente , Lipopolisacáridos/farmacología , Macrófagos Alveolares/inmunología , Ratones , Ratones Endogámicos BALB C , Neutrófilos/citología , Neutrófilos/efectos de los fármacos , Neutrófilos/fisiología , Oligopéptidos/administración & dosificación , Oligopéptidos/agonistas , Oligopéptidos/farmacocinética , Fragmentos de Péptidos/administración & dosificación , Alveolos Pulmonares/efectos de los fármacos , Alveolos Pulmonares/ultraestructura , Receptor PAR-1/análisis , Receptor PAR-1/efectos de los fármacos , Receptor PAR-2/análisis , Receptor PAR-2/efectos de los fármacos , Organismos Libres de Patógenos Específicos , Trombina/administración & dosificación , Trombina/antagonistas & inhibidores , Trombina/farmacocinética , Tráquea/patología , Tripsina/administración & dosificación , Tripsina/efectos adversos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/metabolismo , Factor de Necrosis Tumoral alfa/farmacología , Reino UnidoRESUMEN
Formyl peptide receptor-like 1 (FPRL1) plays a key role in the regulation of immune responses. The activation of FPRL1 induces a complicated pattern of cellular signaling, which results in the regulation of several immune responses, such as chemotactic migration and the production of reactive oxygen species (ROS). Because some of these cellular responses are not beneficial to the host, ligands that selectively modulate these cellular responses are useful. His-Phe-Tyr-Leu-Pro-Met (HFYLPM) is a synthetic peptide that binds to FPRL1. In this study, we generated various HFYLPM analogues and examined their effects on cellular responses via FPRL1 in FPRL1-expressing rat basophilic leukemia-2H3 cells or in primary human neutrophils. Among the HXYLPM analogues, His-Arg-Tyr-Leu-Pro-Met (HRYLPM) activated a broad spectrum of cellular signaling events, including an intracellular Ca(2+) concentration increase, phosphoinositide 3-kinase, extracellular signal-regulated kinase, and Akt activation, however, His-Glu-Tyr-Leu-Pro-Met (HEYLPM) activated only intracellular Ca(2+) concentration and Akt but did not increase Ca(2+). In addition, HRYLPM was found to stimulate chemotaxis and ROS generation via phosphoinositide 3-kinase and an intracellular Ca(2+) concentration increase, respectively, whereas HEYLPM stimulated chemotaxis but not ROS generation. With respect to the molecular mechanisms involved in the differential action of HRYLPM and HEYLPM, we found that HRYLPM but not HEYLPM competitively inhibited the binding of (125)I-labeled Trp-Lys-Tyr-Met-Val-D-Met-NH(2) (WKYMVm, a FPRL1 ligand) to FPRL1. This study demonstrates that the important chemoattractant receptor, FPRL1, may be differentially modulated by distinct peptide ligands. We also suggest that HRYLPM and HEYLPM may be used to selectively modulate FPRL1.
Asunto(s)
Oligopéptidos/metabolismo , Oligopéptidos/farmacología , Proteínas Serina-Treonina Quinasas , Receptores de Formil Péptido/metabolismo , Receptores de Lipoxina/metabolismo , Animales , Calcio/metabolismo , Línea Celular Tumoral , Factores Quimiotácticos/metabolismo , Quimiotaxis de Leucocito/fisiología , Humanos , Líquido Intracelular/metabolismo , Líquido Intracelular/fisiología , Radioisótopos de Yodo/metabolismo , Ligandos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Neutrófilos/metabolismo , Neutrófilos/fisiología , Oligopéptidos/agonistas , Oligopéptidos/síntesis química , Fosforilación , Unión Proteica/fisiología , Proteínas Tirosina Quinasas/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-akt , Ratas , Receptores de Formil Péptido/agonistas , Receptores de Formil Péptido/biosíntesis , Receptores de Lipoxina/agonistas , Receptores de Lipoxina/biosíntesis , Transducción de Señal/fisiología , Superóxidos/metabolismoRESUMEN
The interaction between TCR and peptide-MHC (pMHC) complexes is crucial for the activation of T cells as well as for positive and negative selection in the thymus. The kinetics and affinity of this interaction and the densities of TCR and pMHC complexes on the cell surface are determining factors for different outcomes during thymic selection. In general, it is thought that agonist pMHC, which cause negative selection, have higher affinities and, in particular, slower off-rates than partial or weak agonists and antagonists, which cause positive selection. In this study, we have used pMHC tetramers to investigate the kinetics of TCR-pMHC interaction for agonist, weak agonist, and antagonist ligands of the anti-lymphocytic choriomeningitis virus P14 TCR. Kinetics determined on the cell surface may be biologically more relevant than methods using soluble proteins. We can distinguish between agonists and weak agonists or antagonists based on the half-life and the avidity of tetramer-TCR interaction. Furthermore, we show that a weak agonist self-peptide that positively selects P14 TCR(+) thymocytes has a tetramer half-life and avidity only slightly weaker than strong agonists. We show that, in fact, it can act as quite a strong agonist, but that its poor ability to stabilize MHC causes it instead to have a weak agonist phenotype.
Asunto(s)
Epítopos de Linfocito T/metabolismo , Antígenos H-2/metabolismo , Oligopéptidos/metabolismo , Receptores de Antígenos de Linfocitos T/metabolismo , Sustitución de Aminoácidos/inmunología , Animales , Presentación de Antígeno/inmunología , Unión Competitiva/inmunología , Línea Celular Tumoral , Membrana Celular/inmunología , Membrana Celular/metabolismo , Relación Dosis-Respuesta Inmunológica , Regulación hacia Abajo/inmunología , Semivida , Antígeno de Histocompatibilidad H-2D , Cinética , Activación de Linfocitos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Oligopéptidos/agonistas , Oligopéptidos/antagonistas & inhibidores , Unión Proteica/inmunología , Receptores de Antígenos de Linfocitos T/agonistas , Receptores de Antígenos de Linfocitos T/antagonistas & inhibidores , Receptores de Antígenos de Linfocitos T/biosíntesis , Linfocitos T/inmunología , Linfocitos T/metabolismoRESUMEN
Antagonism of allospecific CTL by altered MHC ligands is a potential approach to specific immunomodulation of allogeneic T cell responses in acute graft rejection and graft-vs-host disease. In this study we have analyzed the capacity of peptide analogs of a natural HLA-B27-allospecific CTL epitope to antagonize direct alloreactivity. Alanine scanning demonstrated that positions 4, 5, and 7 of the peptide epitope were critical for allorecognition. A number of relatively conservative substitutions at each of these positions were then tested for their effect on allorecognition and antagonism. All substitutions at position 5 abrogated cytotoxicity. In contrast, a few changes at positions 4 and 7 were tolerated, indicating a limited flexibility of the allospecific CTL in recognition of peptide epitope variants. Most of the substitutions impairing cytotoxicity actually induced antagonism. However, whereas epitope variants with changes at positions 4 and 7 behaved as weak or intermediate antagonists, some of the variants with changes at position 5 antagonized CTL alloreactivity almost completely. The results in this study demonstrate for the first time that antagonism of direct class I-mediated alloreactivity can be achieved by variants of a natural allospecific peptide epitope.